The prospective French participitation to IDEA (International Duration Evaluation of Adjuvant Chemotherapy) study in stage III colon cancer: Patients' characteristics and safety analysis of 3 versus 6 months of adjuvant chemotherapy.

被引：0
|
作者：
Andre, Thierry
De Gramont, Aimery
Mineur, Laurent
Desrame, Jerome
Faroux, Roger
Bennouna, Jaafar
Dauba, Jerome
Louvet, Christophe
Pernot, Simon
Dupuis, Olivier Jean Marie
Becouarn, Yves
Mabro, May
Egreteau, Joelle
Bouche, Olivier
Bonnetain, Franck
de larauze, Marine Hug
Le Malicot, Karine
Taieb, Julien
机构：
[1] Hop St Antoine, F-75571 Paris, France
[2] Inst Hosp Franco Britann, Levallois Perret, France
[3] Inst St Catherine, Avignon, France
[4] Hop Prive Jean Mermoz, Lyon, France
[5] Ctr Hosp Dept Oudairies, La Roche Sur Yon, France
[6] Inst Cancerol Ouest, Nantes, France
[7] Ctr Hosp Layne, Mt De Marsan, France
[8] Inst Mutualiste Montsouris, Paris, France
[9] Hop Europeen Georges Pompidou, Paris, France
[10] Clin Victor Hugo, Le Mans, France
[11] Inst Bergonie, Bordeaux, France
[12] Hop Foch, Suresnes, France
[13] Ctr Hosp Bretagne Sud, Lorient, France
[14] Ctr Hosp Univ Robert Debre, Reims, France
[15] Ctr Hosp Reg & Univ, Besancon, France
[16] GERCOR, Paris, France
[17] FFCD, Dijon, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期
关键词：
D O I：
10.1200/jco.2016.34.4_suppl.633
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
633
引用
收藏
页数：1
相关论文
共 50 条
  • [1] The Greek participitation to IDEA (International Duration Evaluation of Adjuvant Chemotherapy) study of 3 versus 6 months of adjuvant chemotherapy in stage III colon cancer: Patients' characteristics and safety analysis.
    Souglakos, John
    Boukovinas, Ioannis
    Kakolyris, Stylianos
    Ziras, Nikolaos
    Androulakis, Nikolaos E. M.
    Ardavanis, Alexandros
    Kentepozidis, Nikolaos K.
    Vaslamatzis, Michael
    Athanasiadis, Athanasios
    Christopoulou, Athina
    Makrantonakis, Paris
    Polyzos, Aristidis
    Mavroudis, Dimitrios
    Mala, Anastasia
    Kalisperi, Aggeliki
    Xynogalos, Spyros
    Varthalitis, Ioannis I.
    Kouroussis, Charalambos
    Prinarakis, Efthimios
    Georgoulias, Vassilis
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [2] Three versus six months adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: The French participation to the International Duration Evaluation of Adjuvant chemotherapy (IDEA) project.
    Andre, Thierry
    Bonnetain, Franck
    Mineur, Laurent
    Bennouna, Jaafar
    Desrame, Jerome
    Faroux, Roger
    Dauba, Jerome
    Vernerey, Dewi
    Aissat, Nasredine
    Louvet, Christophe
    Lepere, Celine
    Dupuis, Olivier Jean Marie
    Becouarn, Yves
    Mabro, May
    Egreteau, Joelle
    Bouche, Olivier
    Deplanque, Gael
    Ychou, Marc
    De Gramont, Aimery
    Taieb, Julien
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] IDEA study (International Duration Evaluation of Adjuvant Chemotherapy) for patients with stage III colon cancer: Possibility of reducing to 3 months treatment for 60% of the patients
    Andre, Thierry
    Taieb, Julien
    BULLETIN DU CANCER, 2018, 105 (06) : 546 - 547
  • [4] Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration
    Shi, Qian
    Sobrero, Alberto F.
    Shields, Anthony Frank
    Yoshino, Takayuki
    Paul, James
    Taieb, Julien
    Sougklakos, Ioannis
    Kerr, Rachel
    Labianca, Roberto
    Meyerhardt, Jeffrey A.
    Bonnetain, Franck
    Watanabe, Toshiaki
    Boukovinas, Ioannis
    Renfro, Lindsay A.
    Grothey, Axel
    Niedzwiecki, Donna
    Torri, Valter
    Andre, Thierry
    Sargent, Daniel J.
    Iveson, Timothy
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] Three versus six months adjuvant oxaliplatin plus fluoropyrimidine chemotherapy for patients with stage III colon cancer: The Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant (IDEA) chemotherapy project.
    Souglakos, John
    Boukovinas, Ioannis
    Xynogalos, Spyros
    Kakolyris, Stylianos
    Ziras, Nikolaos
    Vaslamatzis, Michael
    Ardavanis, Alexandros
    Athanasiadis, Athanasios
    Androulakis, Nikolaos E. M.
    Kentepozidis, Nikolaos K.
    Christopoulou, Athina
    Makrantonakis, Paris
    Varthalitis, Ioannis I.
    Christofyllakis, Charalampos
    Emmanouilides, Christos E.
    Mavroudis, Dimitrios
    Prinarakis, Efthimios
    Kalisperi, Aggeliki
    Hatzidaki, Dora
    Georgoulias, Vassilis
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [6] Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): Updated results of IDEA (International Duration Evaluation of Adjuvant chemotherapy)
    Grothey, A.
    Sobrero, A.
    Meyerhardt, J. A.
    Yoshino, T.
    Paul, J.
    Taieb, J.
    Souglakos, I.
    Kerr, R.
    Labianca, R.
    Shields, A. F.
    Bonnetain, F.
    Yamanaka, T.
    Boukovinas, I.
    Shi, Q.
    Meyers, J. P.
    Niedzwiecki, D.
    Torri, V.
    Sargent, D. J.
    Andre, T.
    Iveson, T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [7] Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.
    Shi, Qian
    Sobrero, Alberto F.
    Shields, Anthony Frank
    Yoshino, Takayuki
    Paul, James
    Taieb, Julien
    Sougklakos, Ioannis
    Kerr, Rachel
    Labianca, Roberto
    Meyerhardt, Jeffrey A.
    Bonnetain, Franck
    Watanabe, Toshiaki
    Boukovinas, Ioannis
    Renfro, Lindsay A.
    Grothey, Axel
    Niedzwiecki, Donna
    Torri, Valter
    Andre, Thierry
    Sargent, Daniel J.
    Iveson, Timothy
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (18)
  • [8] Efficacy of 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer (CC): Results from phase III ACHIEVE trial as part of the International Duration Evaluation of Adjuvant therapy (IDEA) Collaboration
    Yoshino, T.
    Yamanaka, T.
    Kotaka, M.
    Manaka, D.
    Eto, T.
    Hasegawa, J.
    Takagane, A.
    Nakamura, M.
    Kato, T.
    Munemoto, Y.
    Nakamura, F.
    Bando, H.
    Taniguchi, H.
    Gamoh, M.
    Shiozawa, M.
    Sakamoto, J.
    Saji, S.
    Mizushima, T.
    Ohtsu, A.
    Mori, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [9] The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status
    Andre, Thierry
    Iveson, Timothy
    Labianca, Roberto
    Meyerhardt, Jeffrey A.
    Souglakos, Ioannis
    Yoshino, Takayuki
    Paul, James
    Sobrero, Alberto
    Taieb, Julien
    Shields, Anthony F.
    Ohtsu, Atsushi
    Grothey, Axel
    Sargent, Daniel J.
    CURRENT COLORECTAL CANCER REPORTS, 2013, 9 (03) : 261 - 269
  • [10] The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?
    Sobrero, A.
    Grothey, A.
    Iveson, T.
    Labianca, R.
    Yoshino, T.
    Taieb, J.
    Maughan, T.
    Buyse, M.
    Andre, T.
    Meyerhardt, J.
    Shields, A. F.
    Souglakos, I
    Douillard, J-Y
    Cervantes, A.
    ANNALS OF ONCOLOGY, 2018, 29 (05) : 1099 - 1107
12345